Articles
The big Australian biopharma
Brian McNamee has been at the helm of Australia's oldest - and now biggest - life-sciences company, CSL, for 15 years. He guided the company through its public listing in 1994 and has overseen its growth to a market capitalisation of $6.8 billion. He spoke with Melissa Trudinger about CSL's research and development programs, and his vision for the company's future. [ + ]
The near-term potential of stem cell therapies
The prospect of therapies based on human stem cells holds great promise for revolutionising the practice of medicine, says Silviu Itescu. [ + ]
A productive dose of medicines
The pressure of healthcare costs in the future will bring better health outcomes, predict Kieran Schneemann and Brendan Shaw. [ + ]
The commercial value and business of human ES cells
The human embryonic stem (ES) cell field is one of the most exciting and complex opportunities of today's biomedical industry, write Peter Mountford and Kenzo Nakajima. [ + ]
Industrial and commercial VOC quantification
Selected ion flow tube mass spectrometry (SIFT-MS) instruments represent the latest generation in the evolutionary path of analytical instruments. SIFT-MS is complementing existing GC-based analytical services as well as opening up entirely new services
[ + ]Making strange or making sense - art and the life sciences
Oron Catts and Ionat Zurr talk about the future with Bioart. [ + ]
ISPE aims to build bridges to biotech
An international conference to be held in Australia next week has particular relevance for the future of Australia's biotech and pharmaceutical industries, writes Iain Scott. [ + ]
The mammalian genome and phenome
Chris Goodnow talks about defining the mammalian phenome and how this may pan out in the future. [ + ]
The hard cell: research debate to fire up again
Melissa Trudinger looks at the issues that are set to arise as debate begins again on stem cell research in Australia. [ + ]
Neuroscience in the future
Max Bennett spoke with Susan Williamson about what's in store for neuroscience in coming years. [ + ]
Beating diabetes
Susan Williamson spoke with eminent scientist Len Harrison about his views for the future of diabetes research. [ + ]
Research prospective
Nigel Poole offers 10 glimpses of what Australian life science commercialisation could look like in 2015. [ + ]
The role of commercialisation in biotechnology
Collaboration and cooperation are key when taking research to market, writes Rowan Gilmore. [ + ]
The pharmaceutical forecast
A new environment for pharmaceutical companies is on the horizon and it will be the fittest who survive, predicts Ian Nisbet. [ + ]
Can life sciences go the IT way?
The life sciences can learn from the IT revolution, Prashant Tyagi explains. [ + ]
